Seer

Seer is a biotechnology company that has developed a platform for proteomics, the large-scale study of proteins. The company's flagship product, the Proteograph, is a platform that enables researchers to conduct deep, unbiased, and rapid analysis of the proteome.

Seer's technology is designed to provide a more comprehensive view of the proteome than was previously possible. This is achieved through a combination of proprietary nanoparticles and software that allows for the selective capture and analysis of proteins from complex biological samples. The company's platform is used by researchers in a variety of fields, including drug discovery, diagnostics, and basic research.

Seer's business model is based on the sale of its Proteograph platform, as well as recurring revenue from the sale of consumables and software. The company's customers include academic and government research institutions, as well as pharmaceutical and biotechnology companies. Seer is a publicly traded company, listed on the Nasdaq stock exchange under the ticker symbol SEER.

Keywords: proteomics, biotechnology, Proteograph, life sciences, genomics, data analysis, drug discovery, research tools, biological insights, multi-omics